Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.

Biological psychiatry - 15 Sept 2007

Lee Anna M, Jepson Christopher, Hoffmann Ewa, Epstein Leonard, Hawk Larry W, Lerman Caryn, Tyndale Rachel F

Abstract excerpt

BACKGROUND: CYP2B6 is the primary enzyme involved in bupropion (Zyban; GlaxoSmithKline, Research Triangle Park, North Carolina) metabolism. Genetic polymorphisms in CYP2B6, such as CYP2B6*6, can alter bupropion metabolism and may affect bupropion treatment outcome. METHODS: Subjects participated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Behavior, Addictive
Share to Bupropion
Share to Cytochrome P-450 CYP2A6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2B6

Share to Oxidoreductases, N-Demethylating

Share to Placebos

Share to Smoking Cessation

Share to Tobacco Use Disorder

Source

Identifiers

PMID: 17223085
DOI: 10.1016/j.biopsych.2006.10.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17223085-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.PMID 17223085Read ↗

Pharmacogenetic investigation of smoking cessation treatment.Semantic proximity Read ↗

Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.Semantic proximity Read ↗

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessationSemantic proximity Read ↗

Association of CYP2B6 genetic polymorphisms with bupropion and hydroxybupropion exposure: A systematic review and meta-analysis.Semantic proximity Read ↗

Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.Semantic proximity Read ↗

Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition.Semantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data.Semantic proximity Read ↗

CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes.Semantic proximity Read ↗

CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy.Semantic proximity Read ↗

The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity.Semantic proximity Read ↗

Effects of Genetic Polymorphisms of Drug Transporter ABCB1 (MDR1) and Cytochrome P450 Enzymes CYP2A6, CYP2B6 on Nicotine Addiction and Smoking CessationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.